Report Overview

The US Biologic drugs for Rheumatoid Arthritis treatment market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

Biologic drugs have proved highly effective for the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA). These drugs are often considered cost-effective for well-defined RA patient populations not responding adequately to conventional treatment. While most traditional meds are made from chemicals and have known structures, biologics are more complex. Theyre typically made from living materials, like animal, human, and bacteria cells. These products represent cutting-edge research and also enable the latest scientific discoveries. Such discoveries can be translated into novel therapies that provide new treatment options for patients. Moreover, an increased understanding of the genetic and molecular basis of disease has opened up the development of a range of targeted treatments



Market Growth Drivers

The market is majorly driven by growing capital investment from the key market players, the rise in the burden of chronic diseases, loss of patent exclusivity of the leading biologic drugs, and growing demand and higher acceptability for innovative therapies

With the growing COVID-19 burden, there is a huge demand for biologics during the pandemic, which might drive market growth. Tobacco use, physical inactivity, alcohol consumption, and unhealthy diets create a risk of dying from non-communicable diseases. Also, the rising geriatric population is much susceptible to chronic diseases that help in increasing the biologics demand

Epidemiology

Out of every 100,000 people, 41 are diagnosed with RA every year. About 1.3 million Americans have RA. Women are about two to three times more likely to get RA than men. Hormones in both genders may play a role in either preventing or triggering it. Rheumatoid Arthritis generally starts between the ages of 30 and 60 in women and somewhat later in life in men. The lifetime risk of developing RA is 3.6% for women and 1.97% for men